
    
      This is a randomised, phase II trial comparing AZD1775 plus pemetrexed and carboplatin
      followed by maintenance AZD1775 and pemetrexed versus pemetrexed and carboplatin followed by
      maintenance pemetrexed in patients with previously untreated metastatic non-squamous NSCLC
      with TP53 mutations. The primary endpoint of the trial is assessment of progression-free
      survival (PFS).
    
  